House Commerce/Health Subcommittee March 20 hearing to include testimony from PhRMA's Lyons.
Executive Summary
HOUSE COMMERCE/HEALTH SUBCOMMITTEE HEARING MARCH 20 is expected to include testimony from former Marion Merrell Dow Chairman Fred Lyons, who heads the Pharmaceutical Research & Manufacturers of America's FDA reform key issue team. Lyons, who is scheduled to retire from Hoechst Marion Roussel, will continue to head PhRMA's FDA reform effort and will retain that role after his term on the PhRMA board expires in April. Former HHS Secretary Louis Sullivan is also understood to be scheduled to appear. In addition, the committee has said previously it wanted FDA Commissioner Kessler to appear at the next hearing. The committee said it would set the hearing date to accommodate Kessler.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth